- Home
- GTES vs RYTM Comparison
GTES vs RYTM Comparison
Compare GTES & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GTES | RYTM |
|---|---|---|
| Founded | 1911 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.6B | 6.3B |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | GTES | RYTM |
|---|---|---|
| Price | $25.48 | $89.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 19 |
| Target Price | $33.25 | ★ $140.53 |
| AVG Volume (30 Days) | ★ 1.7M | 647.4K |
| Earning Date | 10-30-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 29.73 | 28.34 |
| EPS | ★ 0.90 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.93 | $66.07 |
| Revenue Next Year | $5.00 | $79.32 |
| P/E Ratio | $27.91 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.88 | $74.50 |
| 52 Week High | $30.34 | $122.20 |
Technical Indicators
Market Signals| Indicator | GTES | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 41.11 |
| Support Level | $25.21 | $82.92 |
| Resistance Level | $26.97 | $91.70 |
| Average True Range (ATR) | 0.97 | 3.00 |
| MACD | -0.14 | 0.65 |
| Stochastic Oscillator | 33.71 | 48.62 |
Price Performance
Historical ComparisonAbout GTES Gates Industrial Corporation plc
Gates Industrial Corp Ltd operates as a manufacturer of application-specific fluid power and power transmission solutions. Its product portfolio includes engineered components used in power transmission and fluid power applications across a range of end markets and geographic regions.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.